Latest News Releases From The Newsroom
Lockheed Martin Bags $99M Contract; Nasdaq Notifies Enochian Biosciences
July 11th, 2023
Lockheed Martin Rotary and Mission Systems, a business segment of Lockheed Martin Corporation (NYSE: LMT), has been awarded a firm-fixed-price, cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract worth up to $99 million. The cont. Read more
Breaking: Shift Technologies' Strategic Move, Delta Air Lines' Key Upcoming Date
July 11th, 2023
Shift Technologies, Inc. (Nasdaq: SFT) plans to restructure its workforce to align with its omnichannel sales strategy, aimed to enhance the customer experience, increase efficiency, and focus on core operations by eliminating investment in the deale. Read more
SEC Charges Merrill Lynch and Parent Company for Failing to File Suspicious Activity Reports
July 11th, 2023
FOR IMMEDIATE RELEASE 2023-128 Washington D.C. / CRWE PRESS RELEASE / July 11, 2023 - The Securities and Exchange Commission today announced charges against Merrill Lynch, Pierce, Fenner & Smith Incorporated and its parent. Read more
Byrna's Q2 Results Disappoint, electroCore Expects Upbeat Q2 Revenue
July 11th, 2023
Byrna Technologies Inc. (Nasdaq: BYRN) reported a second-quarter fiscal 2023 loss of $0.05 per share and revenue of $11.51 million. These figures fell short of the consensus estimate, which projected earnings per share of $0.01 on revenue of $12 mill. Read more
R100 Vector Deal Fuels 4DMT; ADC Therapeutics Tumbles On ZYNLONTA Trial Status
July 11th, 2023
Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT)(4DMT) have entered into a license agreement, allowing the use of 4DMT's intravitreal retinotropic R100 vector for rare monogenic ophthalmic diseases. This includes one initial ge. Read more
AspyreRx's Approval Boosts Better Therapeutics; Financial Figures, Outlook Drive WD-40, E2open
July 11th, 2023
Shares of Better Therapeutics, Inc. (Nasdaq: BTTX) surged over 20% in after-hours trading as the company received authorization from the FDA for its groundbreaking prescription-only digital therapeutic, AspyreRx. This innovative treatment offers cogn. Read more
CalAmp Posts Loss, Eyes Strategic Options; PriceSmart Posts Mixed Financial Figures
July 10th, 2023
CalAmp Corp. (Nasdaq: CAMP) faced a first-quarter fiscal 2024 loss of $0.11 per share, falling short of the consensus earnings per share estimate of $0.04. Looking ahead, the company expects Q2 FY24 revenues to range between $67 million and $73 mi. Read more
Market Surges: Mobilicom and Novavax See Dramatic Upswing
July 10th, 2023
Shares of Mobilicom Limited (Nasdaq: MOB) climbed over 100% in early trade following the company's announcement of a significant commercial-scale purchase order from Teledyne-FLIR, one of its Tier-1 customers. The purchase order from Teledyne Tech. Read more
Market Turmoil: FMC Slumps on Lowered Revenue Outlook
July 10th, 2023
Shares of FMC Corporation (NYSE: FMC) plummeted over 6% following the release of an update on its second quarter and full-year 2023 outlook. The company now expects second-quarter revenue to be in the range of $1.00 billion to $1.03 billion, signific. Read more
Helen of Troy Beats Estimates; Analysts Take Note of CAVA Group
July 10th, 2023
Helen of Troy Limited (Nasdaq: HELE) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.94, surpassing the consensus estimate of $1.60. Looking ahead, for the full-year fiscal 2024, the company expects adjusted EPS to fall . Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026




Member Login